{"company":{"id":688834,"name":"Roivant","domain":"roivant.com","url":"https://alion.io/company/roivant"},"section":"news","answer":"Roivant: 6 headlines on record, 6 headlines in the last 90 days. Its story counts 2 milestones.","figures":[{"label":"Headlines","value":"6"},{"label":"In 90 days","value":"6"},{"label":"Milestones","value":"2"}],"blocks":[{"key":"news","title":"Headlines","source":"the outlets named on each headline, each story once","rows":6},{"key":"story","title":"Milestones","source":"Each milestone is dated by its source: registers, filings, the press","rows":2}],"news":[{"date":"2026-09-22","kind":"News","title":"Roivant Sciences Ltd. (ROIV) Presents at Bank of America Global Healthcare Conference 2026 Transcript","source":"seekingalpha.com","url":"https://seekingalpha.com/article/4948644-roivant-sciences-ltd-roiv-presents-at-bank-of-america-global-healthcare-conference-2026"},{"date":"2026-09-10","kind":"News","title":"Roivant is one of the savviest dealmakers in biotech. It also has a secret weapon","source":"STAT","url":"https://statnews.com/2026/09/10/roivant-biotech-dealmaking-mosliciguat-origins/"},{"date":"2026-09-09","kind":"News","title":"Roivant Reports 56.3% Placebo-Adjusted PVR Reduction In Phase 2 Mosliciguat PH-ILD Study, Starts Phase 3 PHrontier Trial","source":"Pulse 2.0","url":"https://pulse2.com/roivant-reports-56-3-placebo-adjusted-pvr-reduction-in-phase-2-mosliciguat-ph-ild-study-starts-phase-3-phrontier-trial/"},{"date":"2026-09-08","kind":"News","title":"Roivant climbs on mid-stage trial win for lung disease candidate","source":"seekingalpha.com","url":"https://seekingalpha.com/news/4640683-roivant-stock-climbs-mid-stage-trial-win"},{"date":"2026-09-08","kind":"News","title":"Roivant's $14M bet on Bayer's inhaled hypertension med pays off with phase 2 win","source":"fiercebiotech.com","url":"https://fiercebiotech.com/biotech/roivants-14m-bet-bayers-inhaled-hypertension-med-pays-phase-2-win"},{"date":"2026-08-28","kind":"News","title":"Roivant Announces FDA Approval of LISRAYA (brepocitinib) for Adults with Dermatomyositis; Now Available in the U.S.","source":"markets.businessinsider.com","url":"https://markets.businessinsider.com/news/stocks/roivant-announces-fda-approval-of-lisraya-brepocitinib-for-adults-with-dermatomyositis-now-available-in-the-u-s-1036499966"}],"story":[{"title":"Certified Roivant Announces FDA Approval of LISRAYA (brepocitinib) for Adults with Dermatomyositis; Now Available in the U.S. · markets.businessinsider.com","url":"https://markets.businessinsider.com/news/stocks/roivant-announces-fda-approval-of-lisraya-brepocitinib-for-adults-with-dermatomyositis-now-available-in-the-u-s-1036499966"},{"title":"Founded"}],"as_of":"2026-11-16","cite":"Roivant, News. Alion, Nov 16, 2026. https://alion.io/company/roivant/news","html_url":"https://alion.io/company/roivant/news","json_url":"https://alion.io/company/roivant/news.json","license":"CC BY-SA 4.0","meta":{"source":"Alion","generated_at":"2026-11-16T00:15:04Z"}}